All articles by
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
Study demonstrated the DMT’s effectiveness as a melanoma rule-out test for all skin types
Sun Pharma to acquire remaining stake in Israel-based Taro for $348m
Upon completion of the merger, expected to be completed in the first half of this year, Taro will become a privately held entity and its shares will be delisted from the New York Stock Exchange
Thermo Fisher rolls out CTS Cellmation Software to automate cell therapy workflows
The Gibco CTS Cellmation Software is designed to connect and integrate workflows across several Thermo Fisher Scientific cell therapy instruments to streamline and automate manufacturing
Rad AI partners with Google to advance radiology reporting with AI
Rad AI will use Google Cloud’s platform and AI tools, including MedLM, a family of foundation models fine-tuned for healthcare industry use cases, and Gemini-based models in the future, with Google Cloud serving as a preferred cloud provider
Takeda’s Hyqvia secures US FDA approval to treat adults with CIDP
The US FDA has approved Hyqvia as a maintenance therapy to inhibit the relapse of neuromuscular disability and impairment in adults
Vertex gets FDA nod for Casgevy to treat transfusion-dependent beta thalassemia
Previously known as CTX-001, Casgevy is a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease or TDT
EC clears Roche’s Tecentriq SC as subcutaneous injection for multiple cancers
The approval was based on results from the Phase IB/III IMscin001 study which showed the SC formulation showed comparable levels of Tecentriq in the blood
NeuPath announces clinic acquisition
Acquired the assets of SIBI Medical, operating as the London Spine Institute, adding back, neck and spine specialists to enhance our care options for patients
US FDA grants orphan drug status to HKBU’s herbal medicine for myofibrillar myopathy
CDD-2107 is made using effective components of Chinese herbal medicine, Chaenomelis Fructus, to treat myofibrillar myopathy and has become the first botanical drug in Hong Kong to receive this designation
GSK gets China’s NMPA approval for Nucala to treat severe eosinophilic asthma
The approval was based on positive data from a Phase 3 trial in which patients who received Nucala experienced 65% fewer clinically significant exacerbations